PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-57.23%
Negative revenue growth signals a shrinking top line, alarming for Benjamin Graham. Confirm if it’s cyclical or structural before proceeding.
-57.23%
Negative gross profit growth suggests either falling sales or rising direct costs. Benjamin Graham would consider this a fundamental warning sign.
5.53%
EBIT growth 5-10% – Moderate. Peter Lynch might look for ways the firm could optimize costs to boost EBIT further.
5.53%
Operating income growth 5-10% – Moderate. Peter Lynch would evaluate product-level profitability to see if certain segments could accelerate growth.
5.62%
Net income growth 5-10% – Moderate. Philip Fisher would look at whether incremental improvements can accelerate with scale.
13.79%
EPS growth 10-15% – Solid. Seth Klarman would see if share dilution or buybacks significantly affected the results.
13.79%
Diluted EPS growth 10-15% – Solid. Seth Klarman would check if share-based compensation is offsetting part of net income gains.
10.10%
Share count growth exceeding +3% – Notable dilution. Philip Fisher would want justification for new share issuance or acquisitions.
10.10%
Diluted share count growth above 3% – Noticeable dilution. Philip Fisher would question the rationale for issuing more stock or options.
No Data
No Data available this quarter, please select a different quarter.
18.75%
OCF growth 15-20% – Very strong. Benjamin Graham would ensure that working capital changes aren’t inflating short-term cash flow artificially.
17.73%
FCF growth 15-20% – Strong. Benjamin Graham might verify whether large asset sales or one-time items artificially boosted free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1028.36%
A negative 10Y OCF/share CAGR signals erosion in long-term cash generation. Benjamin Graham would label this as a major red flag.
94.36%
5Y OCF/share CAGR above 15% – Very robust mid-term cash expansion. Warren Buffett would check if reinvestment fosters sustainable growth.
80.21%
3Y OCF/share CAGR above 15% – Rapid short-term expansion. Warren Buffett would see if this stems from genuine operational improvements vs. working-capital swings.
-551.14%
A negative 10Y net income/share CAGR reflects a decade of weakening profits. Benjamin Graham would be extremely cautious unless a turnaround is evident.
94.20%
5Y net income/share CAGR above 15% – Strong mid-term profit growth. Benjamin Graham would check if leverage artificially boosts earnings.
81.22%
3Y net income/share CAGR above 15% – Rapid short-term profit growth. Benjamin Graham would verify if it’s driven by core revenue or temporary cost reductions.
1992.70%
10Y equity/share CAGR above 12% – Excellent long-term book value compounding. Warren Buffett would see if consistent profits plus moderate payouts drive this growth.
-67.70%
Negative 5Y equity/share CAGR suggests net worth destruction. Benjamin Graham would see if failing profitability or large payouts cause it.
-15.48%
Negative 3Y equity/share CAGR means a near-term drop in book value. Benjamin Graham would be cautious unless restructured operations promise a future rebound.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
12.46%
Asset growth 10-15% – Moderate. Seth Klarman sees if expansions or new facilities can increase ROA in tandem.
3.36%
2-5% annual BV/share growth – Mild. Peter Lynch sees potential if expansions or margin lifts can accelerate compounding.
-16.56%
A negative growth rate in debt means deleveraging, often positive for conservative investors. Benjamin Graham confirms it doesn’t restrict needed investments.
-15.08%
A big drop in R&D might boost near-term earnings but risk starving the pipeline. Benjamin Graham sees if the firm is refocusing or if future growth suffers.
-0.47%
Shrinking SG&A can raise profits short term, but might risk cutting key growth drivers. Benjamin Graham sees if this is sustainable.